Court reinstates Pfizer whistleblower suit

A Pfizer whistleblower will get his day in court. Dr. Peter Rost (photo) accused the company of illegally marketing Genotropin, a human growth hormone product; he filed suit after he lost his job (he was a VP at Pharmacia when Pfizer bought the company). Info in Rost's suit led to a $34.7 million fine against Pfizer, but a federal district court threw out his complaint.

Now, the U.S. Court of Appeals has overruled the lower court. The suit will be reinstated, and Rost will have a chance to amend it. The upshot? Rost may get a share of that $34.7 million fine, and Pfizer may be vulnerable to additional fines. The drugmaker said in a statement that it's confident it will prevail--and emphasized that it was Pharmacia that promoted Genotropin for youth, beauty, and athletic prowess.

- check out Pfizer's statement at Rost's blog
- read this Pharmalot item

Related Articles:
Pfizer leaves exec dangling. Report
Grassley: Whistleblowers, call me. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.